Company intelligence / Profile preview

Aeovian Pharmaceuticals

Berkeley, California, United Statesaeovian.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Aeovian’s lead candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor, entered Phase 1 trials in early 2024 to assess safety in healthy volunteers. The company recently raised $50 million to support this trial and prepare for Phase 2 studies in TSC refractory epilepsy. No efficacy results have been reported yet.

Therapeutic areas: OtherRare DiseasesNeurology
Modalities: Small molecules (selective mTORC1 inhibitors, CD38 inhibitors)
Industry: Biotech

Drug pipeline

5 assets

AV078

4 more assets in the full pipeline.

Request access →

Partnerships

Hevolution Foundation (lead investor with board representation)No major pharma partnerships disclosed as of May 2025.

Beyond the preview

Go deeper on Aeovian Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeovian Pharmaceuticals.

Explore the full profile